Global Finance News
07 Nov 2026, 11:45
Gilead’s Twice-Yearly Lenacapavir Shows Nearly Double the PrEP Persistence of Daily Oral Therapy
Gilead Sciences (NASDAQ: GILD) reported new Phase 2 data showing that twice-yearly injectable lenacapavir achieved substantially higher one-year persistence than daily oral F/TDF for HIV prevention.
At Week 52, 85.6% of participants receiving lenacapavir remained persistent on PrEP, compared with 46.3% of those taking daily oral F/TDF. The 39.3 percentage-point difference was statistically significant.
No HIV acquisitions occurred among participants receiving lenacapavir during the 52-week study, while one case was reported in the F/TDF group, where drug-level testing indicated very limited adherence.
Safety results were generally consistent with prior lenacapavir studies. Serious adverse events were uncommon, and no participant discontinued lenacapavir because of adverse events, although injection-site reactions were frequent.
The results strengthen Gilead’s case that long-acting HIV prevention could address one of the biggest limitations of daily PrEP: maintaining consistent use over time. The company is also evaluating once-yearly lenacapavir as part of its broader long-acting HIV prevention strategy.
Gilead Sciences (NASDAQ: GILD) reported new Phase 2 data showing that twice-yearly injectable lenacapavir achieved substantially higher one-year persistence than daily oral F/TDF for HIV prevention.
At Week 52, 85.6% of participants receiving lenacapavir remained persistent on PrEP, compared with 46.3% of those taking daily oral F/TDF. The 39.3 percentage-point difference was statistically significant.
No HIV acquisitions occurred among participants receiving lenacapavir during the 52-week study, while one case was reported in the F/TDF group, where drug-level testing indicated very limited adherence.
Safety results were generally consistent with prior lenacapavir studies. Serious adverse events were uncommon, and no participant discontinued lenacapavir because of adverse events, although injection-site reactions were frequent.
The results strengthen Gilead’s case that long-acting HIV prevention could address one of the biggest limitations of daily PrEP: maintaining consistent use over time. The company is also evaluating once-yearly lenacapavir as part of its broader long-acting HIV prevention strategy.
